AFPL
IBRX icon

Advus Financial Partners, LLC’s ImmunityBio IBRX Stock Holding History

Advus Financial Partners, LLC’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,751
Closed -$36.3K – 263
2025
Q3 		$36.3K Buy
+14,751
New +$38K 0.01% 255

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Advus Financial Partners, LLC's IBRX Position: Q4 2025 in Review

Advus Financial Partners, LLC sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 14,751 shares — an estimated $36.3K sold.

Advus Financial Partners, LLC first reported a position in IBRX in Q3 2025 and held it in 1 quarter. The position peaked at $36.3K in Q3 2025. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Advus Financial Partners, LLC reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Advus Financial Partners, LLC sold 14,751 ImmunityBio shares in Q4 2025, an estimated $36.3K.
  • Advus Financial Partners, LLC first reported a position in ImmunityBio in Q3 2025 and held it in 1 quarter.
  • Advus Financial Partners, LLC's ImmunityBio position peaked at $36.3K in Q3 2025.
  • 278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Advus Financial Partners, LLC's 13F filing for Q4 2025, filed 25 Aug 2026.